Pharmacopeia axes staff in second round of cuts

In its second big round of cuts in three months, Pharmacopeia says it is axing 40 percent of its staffers. That amounts to 64 workers, according to the Star-Ledger. Last May, the developer axed 15 percent of its staff.

Pharmacopeia says it will begin a Phase II clinical trial for PS433540, focusing on the indication of diabetic nephropathy. "The company is also considering opportunities to partner the development of PS433540 for various indications and is evaluating various strategic initiatives intended to further the development of the company's business and enhance shareholder value," according to a statement

PS433540 delivered promising data in a mid-stage trial last May, demonstrating its ability to reduce blood pressure in patients with mild to moderate hypertension. Seven more therapies are in the clinic, and some have been partnered with Schering-Plough and Bristol-Myers Squibb.

- read Pharmacopeia'a release

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."